| Literature DB >> 9494773 |
C J Elias1, C Coggins, F Alvarez, V Brache, I S Fraser, M Lacarra, P Lähteenmäki, R Massai, D R Mishell, D M Phillips, A M Salvatierra.
Abstract
There is an urgent need to develop safe, effective, and acceptable vaginal products for the prevention of sexually transmitted infections. Preliminary in vitro results suggest that vaginal formulations of sulfated polysaccharides, including iota-carrageenan, have the potential to block mucosal transmission of human immunodeficiency virus (HIV). Twenty-five women in five sites participated in Phase I trials to evaluate the safety of a formulation containing iota-carrageenan (PC 213). The results of this study indicate that a 5 mL 2% gel formulation of iota-carrageenan is not associated with significant irritation of the female reproductive tract when administered once daily in the absence of sexual intercourse. Given the small number of participants in this initial study, careful observation for potential irritation must also be included in larger studies of this and other vaginal formulations.Entities:
Keywords: Acquired Immunodeficiency Syndrome--prevention and control; Americas; Australia; Caribbean; Chile; Clinical Research; Colposcopy; Contraception; Contraceptive Methods; Contraceptive Usage; Developed Countries; Developing Countries; Diseases; Dominican Republic; Endoscopy; Europe; Examinations And Diagnoses; Family Planning; Finland; Hiv Infections--prevention and control; In Vitro; Infections; Latin America; Method Acceptability; North America; Northern America; Northern Europe; Oceania; Physical Examinations And Diagnoses; Reproductive Tract Infections; Research Methodology; Research Report; Scandinavia; Sexually Transmitted Diseases--prevention and control; South America; United States; Vaginal Abnormalities; Vaginal Injury; Vaginal Jelly; Vaginal Spermicides; Viral Diseases
Mesh：
Substances：
Year: 1997 PMID： 9494773 DOI： 10.1016/s0010-7824(97)00176-5
Source DB: PubMed Journal: Contraception ISSN： 0010-7824 Impact factor: 3.375